ASTRAZENECA ANNOUNCES DETAILS OF CHIEF EXECUTIVE OFFICER PASCAL SORIOT’S REMUNERATION
AstraZeneca is today making a regulatory disclosure following the grant of share awards to the company’s new Chief Executive Officer Pascal Soriot in compensation for the forfeiture of long-term incentives from his previous employer. Additionally, the Company is providing details of Pascal Soriot’s remuneration package. AstraZeneca’s executives are incentivised with a mix of salary, bonus and share elements to align their interests with those of shareholders in order to promote AstraZeneca’s success and competitiveness in the pharmaceutical sector. Pascal Soriot’s remuneration has the